$PFE

PFIZER INC

CIK:0000078003|SEC Filings
v3.25.3
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) - USD ($)
shares in Millions, $ in Millions
3 Months Ended 9 Months Ended
Sep. 28, 2025
Sep. 29, 2024
Sep. 28, 2025
Sep. 29, 2024
Alliance revenues $ 2,298 $ 1,900 $ 6,684 $ 6,140
Total revenues 16,654 17,702 45,022 45,864
Costs and expenses:        
Cost of sales [1] 4,172 5,263 10,795 11,942
Selling, informational and administrative expenses [1] 3,186 3,244 9,632 10,456
Research and development expenses [1] 2,546 2,598 7,231 7,787
Acquired in-process research and development expenses 1,390 13 1,401 20
Amortization of intangible assets 1,223 1,312 3,644 3,927
Restructuring charges and certain acquisition-related costs 286 313 945 1,669
Other (income)/deductions––net 517 243 2,210 2,030
Income from continuing operations before provision/(benefit) for taxes on income [2] 3,334 4,715 9,162 8,033
Provision/(benefit) for taxes on income (216) 234 (264) 393
Income from continuing operations 3,550 4,481 9,427 7,640
Discontinued operations––net of tax 0 (8) 25 4
Net income before allocation to noncontrolling interests 3,550 4,473 9,452 7,644
Less: Net income attributable to noncontrolling interests 9 8 33 23
Net income attributable to Pfizer Inc. common shareholders $ 3,541 $ 4,465 $ 9,419 $ 7,621
Earnings per common share––basic:        
Income from continuing operations attributable to Pfizer Inc. common shareholders (in dollars per share) $ 0.62 $ 0.79 $ 1.66 $ 1.35
Discontinued operations––net of tax (in dollars per share) 0 0 0 0
Net income attributable to Pfizer Inc. common shareholders (in dollars per share) 0.62 0.79 1.66 1.35
Earnings per common share––diluted:        
Income from continuing operations attributable to Pfizer Inc. common shareholders (in dollars per share) 0.62 0.79 1.65 1.34
Discontinued operations––net of tax (in dollars per share) 0 0 0 0
Net income attributable to Pfizer Inc. common shareholders (in dollars per share) $ 0.62 $ 0.78 $ 1.65 $ 1.34
Weighted-average shares--basic (in shares) 5,685 5,667 5,682 5,663
Weighted-average shares--diluted (in shares) 5,714 5,705 5,710 5,699
Product [Member]        
Revenues $ 13,920 $ 15,417 $ 37,168 $ 38,731
Royalty [Member]        
Revenues $ 436 $ 384 $ 1,170 $ 992
[1] Exclusive of amortization of intangible assets.
[2] Income from continuing operations before provision/(benefit) for taxes on income. Effective in the third quarter of 2025, certain costs for corporate affairs, which were previously reported in the operating results of corporate enabling functions, are reported in the operating results of our Biopharma reportable segment. In connection with this reporting change, we reclassified costs of approximately $74 million in the first six months of 2025, $50 million in the third quarter of 2024 and $132 million in the first nine months of 2024 from Other business activities to Biopharma to conform to the current period presentation.